We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

216 hedge funds and large institutions have $3.86B invested in Amicus Therapeutics in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 82 increasing their positions, 73 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

132% more call options, than puts

Call options by funds: $11.5M | Put options by funds: $4.95M

17% more capital invested

Capital invested by funds: $3.3B → $3.86B (+$557M)

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

12% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 73

2.67% more ownership

Funds ownership: 105.31%107.98% (+2.7%)

4% less funds holding

Funds holding: 226216 (-10)

22% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 32

Holders
216
Holders Change
-10
Holders Change %
-4.42%
% of All Funds
3.39%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.11%
New
25
Increased
82
Reduced
73
Closed
32
Calls
$11.5M
Puts
$4.95M
Net Calls
+$6.55M
Net Calls Change
+$8.49M
Name Holding Trade Value Shares
Change
Change in
Stake
Royal Bank of Canada
76
Royal Bank of Canada
Ontario, Canada
$3.17M -$143K -12,028 -5%
UBS AM
77
UBS AM
Illinois
$3.01M
SEI Investments
78
SEI Investments
Pennsylvania
$3M -$349K -29,376 -11%
Two Sigma Advisers
79
Two Sigma Advisers
New York
$2.96M -$2.39M -201,000 -46%
Man Group
80
Man Group
United Kingdom
$2.79M +$2.64M +222,504 New
Mirae Asset Global Investments
81
Mirae Asset Global Investments
South Korea
$2.75M +$108K +9,088 +4%
DekaBank Deutsche Girozentrale
82
DekaBank Deutsche Girozentrale
Germany
$2.73M
State of New Jersey Common Pension Fund D
83
State of New Jersey Common Pension Fund D
New Jersey
$2.67M +$416K +35,017 +20%
Legal & General Group
84
Legal & General Group
United Kingdom
$2.64M -$392K -33,060 -14%
AA
85
ALPS Advisors
Colorado
$2.63M +$2.48M +209,179 New
GTC
86
Ghost Tree Capital
New York
$2.51M -$3.26M -275,000 -58%
WCM
87
Wedge Capital Management
North Carolina
$2.44M -$280K -23,559 -11%
State of Wisconsin Investment Board
88
State of Wisconsin Investment Board
Wisconsin
$2.32M -$116K -9,795 -5%
MOACM
89
Mutual of America Capital Management
New York
$2.28M -$164K -13,855 -7%
BNP Paribas Financial Markets
90
BNP Paribas Financial Markets
France
$2.03M -$1.45M -122,086 -43%
BCI
91
Brinker Capital Investments
Pennsylvania
$2M -$65K -5,476 -3%
OPS
92
Orion Portfolio Solutions
Nebraska
$2M -$65K -5,476 -3%
Hudson Bay Capital Management
93
Hudson Bay Capital Management
Connecticut
$1.95M +$356K +30,000 +24%
MIM
94
MetLife Investment Management
New Jersey
$1.87M +$26.6K +2,243 +2%
Envestnet Asset Management
95
Envestnet Asset Management
Illinois
$1.83M +$2.96K +249 +0.2%
AIG
96
American International Group
New York
$1.7M +$22.2K +1,872 +1%
AA
97
AlphaCentric Advisors
Puerto Rico
$1.66M +$1.57M +132,500 New
Jane Street
98
Jane Street
New York
$1.56M +$221K +18,665 +18%
PA
99
Profund Advisors
Maryland
$1.52M +$86.5K +7,288 +6%
AQR Capital Management
100
AQR Capital Management
Connecticut
$1.52M +$30.5K +2,570 +2%

FOLD Hedge Fund Activity: Q2 2023 in Review

216 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q2 2023, worth a combined $3.86B — up 17% from $3.3B a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of FOLD and 25 opened new positions — a net loss of 7 holders — while 73 trimmed existing stakes and 82 added.

The largest buyer was Deutsche Bank, adding an estimated $61.1M. The largest seller was Morgan Stanley, cutting an estimated $40.8M.

  • 216 institutional investors held Amicus Therapeutics (FOLD) as of Q2 2023, down from 226 in Q1 2023.
  • Funds reported $3.86B of Amicus Therapeutics stock for Q2 2023, up 17% quarter-over-quarter.
  • 25 funds opened new Amicus Therapeutics positions in Q2 2023 and 32 closed out, a net change of -7 holders.
  • The largest Amicus Therapeutics buyer in Q2 2023 was Deutsche Bank, an estimated $61.1M added.
  • The largest Amicus Therapeutics seller in Q2 2023 was Morgan Stanley, an estimated $40.8M sold.

Based on aggregated 13F filings for Q2 2023.